Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Wolfgang Janni; Hans Christian Kolberg; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Christian Jackisch; Frederik Marme; Manuel Hörner; Katharina Keller; Chloë Goossens; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P. Lux; Maggie Banys-Paluchowski; Achim Wöckel; Nadia Harbeck; Elmar Stickeler; Rupert Bartsch; Bahriye Aktas; Andreas Schneeweiss; Johannes Ettl; Florin Andrei Taran; Diana Lüftner; Rachel Würstlein; Julia C. Radosa

doi:10.1055/a-2533-2783

Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Wolfgang Janni
, Hans Christian Kolberg
, Andreas D. Hartkopf
, Tanja N. Fehm
, Manfred Welslau
, Volkmar Müller
, Florian Schütz
, Peter A. Fasching^*
, Christian Jackisch
, Frederik Marme
, Manuel Hörner
, Katharina Keller
, Chloë Goossens
, Erik Belleville
, Michael Untch
, Marc Thill
, Hans Tesch
, Nina Ditsch
, Michael P. Lux
, Maggie Banys-Paluchowski

Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C. Radosa

^*Corresponding author for this work

University of Ulm
Marienhospital Bottrop
University of Tubingen
University of Düsseldorf
Hospital Aschaffenburg-Alzenau
University Hospital Hamburg-Eppendorf
Diakonissen-Stiftungs-Krankenhaus
University of Erlangen–Nuremberg
Kliniken Essen-Mitte
University of Mannheim
ClinSol GmbH & Co KG
HELIOS Klinikum Berlin-Buch
Agaplesion Markus Krankenhaus
Centrum für Hämatologie und Onkologie Bethanien
University Hospital Augsburg
St. Vincenz Hospital
University of Würzburg
Ludwig-Maximilians-Universität
RWTH Aachen University
University of Vienna
University of Leipzig
Ruprecht-Karls Universität Heidelberg
Klinik für Frauenheilkunde und Gynäkologie
University of Freiburg
Immanuel Hospital Märkische Schweiz
Medical University of Brandenburg Theodor Fontane
Saarland University

3 Citations (Scopus)

Abstract

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

Translated title of the contribution	Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms
Original language	English
Journal	Geburtshilfe und Frauenheilkunde
Volume	85
Issue number	5
Pages (from-to)	493-506
Number of pages	14
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2533-2783
Publication status	Published - 15.05.2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

Access to Document

10.1055/a-2533-2783

Cite this

Janni, W., Kolberg, H. C., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., Hörner, M., Keller, K., Goossens, C., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., ... Radosa, J. C. (2025). Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 85(5), 493-506. https://doi.org/10.1055/a-2533-2783

@article{f814e53fff8e484db90576ad1e0adeb4,

title = "Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer",

abstract = "This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.",

author = "Wolfgang Janni and Kolberg, \{Hans Christian\} and Hartkopf, \{Andreas D.\} and Fehm, \{Tanja N.\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A.\} and Christian Jackisch and Frederik Marme and Manuel H{\"o}rner and Katharina Keller and Chlo{\"e} Goossens and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, \{Michael P.\} and Maggie Banys-Paluchowski and Achim W{\"o}ckel and Nadia Harbeck and Elmar Stickeler and Rupert Bartsch and Bahriye Aktas and Andreas Schneeweiss and Johannes Ettl and Taran, \{Florin Andrei\} and Diana L{\"u}ftner and Rachel W{\"u}rstlein and Radosa, \{Julia C.\}",

note = "Publisher Copyright: {\textcopyright} 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",

year = "2025",

month = may,

day = "15",

doi = "10.1055/a-2533-2783",

language = "English",

volume = "85",

pages = "493--506",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "5",

}

Janni, W, Kolberg, HC, Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Jackisch, C, Marme, F, Hörner, M, Keller, K, Goossens, C, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Banys-Paluchowski, M, Wöckel, A, Harbeck, N, Stickeler, E, Bartsch, R, Aktas, B, Schneeweiss, A, Ettl, J, Taran, FA, Lüftner, D, Würstlein, R & Radosa, JC 2025, 'Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, vol. 85, no. 5, pp. 493-506. https://doi.org/10.1055/a-2533-2783

TY - JOUR

T1 - Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

AU - Janni, Wolfgang

AU - Kolberg, Hans Christian

AU - Hartkopf, Andreas D.

AU - Fehm, Tanja N.

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A.

AU - Jackisch, Christian

AU - Marme, Frederik

AU - Hörner, Manuel

AU - Keller, Katharina

AU - Goossens, Chloë

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P.

AU - Banys-Paluchowski, Maggie

AU - Wöckel, Achim

AU - Harbeck, Nadia

AU - Stickeler, Elmar

AU - Bartsch, Rupert

AU - Aktas, Bahriye

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Taran, Florin Andrei

AU - Lüftner, Diana

AU - Würstlein, Rachel

AU - Radosa, Julia C.

N1 - Publisher Copyright: © 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2025/5/15

Y1 - 2025/5/15

N2 - This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

AB - This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

UR - https://www.scopus.com/pages/publications/105005591411

UR - https://www.mendeley.com/catalogue/b16fd482-362c-3a26-889d-6df2dc94f3da/

U2 - 10.1055/a-2533-2783

DO - 10.1055/a-2533-2783

M3 - Scientific review articles

C2 - 40386499

AN - SCOPUS:105005591411

SN - 0016-5751

VL - 85

SP - 493

EP - 506

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 5

ER -

Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Abstract

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Cite this